{"id":11212,"date":"2020-10-09T00:00:00","date_gmt":"2020-10-09T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/"},"modified":"2025-08-19T08:28:18","modified_gmt":"2025-08-19T13:28:18","slug":"nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/","title":{"rendered":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS)"},"content":{"rendered":"<p>SpringWorks Therapeutics, Inc. (Nasdaq&nbsp;: SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE&nbsp;: PFE) pour \u00e9valuer l\u2019inhibiteur de la gamma-s\u00e9cr\u00e9tase (GSI) exp\u00e9rimental de SpringWorks Therapeutics, le nirogacestat, en association avec l\u2019anticorps bisp\u00e9cifique CD3 de l\u2019antig\u00e8ne de maturation des lymphocytes B (BCMA) de Pfizer, PF-06863135, chez les patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire.<\/p>\n<p>Cliquez <a href=\"https:\/\/www.morningstar.com\/news\/globe-newswire\/8062618\/springworks-therapeutics-announces-clinical-collaboration-with-pfizer-inc-to-evaluate-nirogacestat-in-combination-with-pf06863135-in-patients-with-relapsed-or-refractory-multiple-myeloma\" target=\"_blank\" rel=\"noopener\"><strong>ici<\/strong><\/a> pour lire l\u2019article complet.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SpringWorks Therapeutics, Inc. (Nasdaq&nbsp;: SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE&nbsp;: PFE) pour \u00e9valuer l\u2019inhibiteur de [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11212","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \u00e9valuer l\u2019inhibiteur de\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS) | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \u00e9valuer l\u2019inhibiteur de\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-10-09T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:18+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS) | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \u00e9valuer l\u2019inhibiteur de\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#blogposting\",\"name\":\"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE R\\u00c9CIDIVANT OU R\\u00c9FRACTAIRE (EN ANGLAIS) | My\\u00e9lome Canada\",\"headline\":\"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE R\\u00c9CIDIVANT OU R\\u00c9FRACTAIRE (EN ANGLAIS)\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2020-10-09T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:18-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#listItem\",\"name\":\"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE R\\u00c9CIDIVANT OU R\\u00c9FRACTAIRE (EN ANGLAIS)\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#listItem\",\"position\":4,\"name\":\"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE R\\u00c9CIDIVANT OU R\\u00c9FRACTAIRE (EN ANGLAIS)\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/\",\"name\":\"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\\u2019UN MY\\u00c9LOME MULTIPLE R\\u00c9CIDIVANT OU R\\u00c9FRACTAIRE (EN ANGLAIS) | My\\u00e9lome Canada\",\"description\":\"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\\u00e9t\\u00e9 biopharmaceutique en phase clinique qui se consacre au d\\u00e9veloppement de m\\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\\u00e9 aujourd\\u2019hui avoir conclu un accord de collaboration en mati\\u00e8re d\\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \\u00e9valuer l\\u2019inhibiteur de\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2020\\\/10\\\/09\\\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2020-10-09T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:18-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS) | My\u00e9lome Canada","description":"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \u00e9valuer l\u2019inhibiteur de","canonical_url":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#blogposting","name":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS) | My\u00e9lome Canada","headline":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS)","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2020-10-09T00:00:00-05:00","dateModified":"2025-08-19T08:28:18-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#listItem","name":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS)"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#listItem","position":4,"name":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS)","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/","name":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS) | My\u00e9lome Canada","description":"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \u00e9valuer l\u2019inhibiteur de","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2020-10-09T00:00:00-05:00","dateModified":"2025-08-19T08:28:18-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS) | My\u00e9lome Canada","og:description":"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \u00e9valuer l\u2019inhibiteur de","og:url":"https:\/\/myeloma.ca\/fr\/2020\/10\/09\/nirogacestat-en-association-avec-pf-06863135-pour-traiter-les-patients-atteints-dun-myelome-multiple-recidivant-ou-refractaire-en-anglais\/","article:published_time":"2020-10-09T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:18+00:00","twitter:card":"summary_large_image","twitter:title":"NIROGACESTAT EN ASSOCIATION AVEC PF-06863135 POUR TRAITER LES PATIENTS ATTEINTS D\u2019UN MY\u00c9LOME MULTIPLE R\u00c9CIDIVANT OU R\u00c9FRACTAIRE (EN ANGLAIS) | My\u00e9lome Canada","twitter:description":"SpringWorks Therapeutics, Inc. (Nasdaq : SWTX), une soci\u00e9t\u00e9 biopharmaceutique en phase clinique qui se consacre au d\u00e9veloppement de m\u00e9dicaments susceptibles de changer la vie des patients atteints de maladies rares graves et de cancers, a annonc\u00e9 aujourd\u2019hui avoir conclu un accord de collaboration en mati\u00e8re d\u2019essais cliniques avec Pfizer Inc. (NYSE : PFE) pour \u00e9valuer l\u2019inhibiteur de"},"aioseo_meta_data":{"post_id":"11212","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:00:34","updated":"2026-04-30 07:22:12","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11212"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11212\/revisions"}],"predecessor-version":[{"id":31308,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11212\/revisions\/31308"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}